early postnatal corticosteroid therapy by Shah and Ohlsson (16) was updated by incorporating data from two subsequently published studies (19, 25) . Infants studied were preterm, demonstrated respiratory distress syndrome on chest radiographs and required mechanical ventilation with oxygen at the time of enrollment (8) (9) (10) (11) 13, 16, 19, 25) . Systemic corticosteroids were given intravenously within 96 h of birth; dexamethasone was used in all but two studies (29, 30) . The most commonly used dosages were 0.5 mg/kg body weight per day for three days, followed by a tapering course of 0.25, 0.125 and 0.05 mg/kg/day each for three days (13, 16) . One study (19) used a considerably lower dosage (0.15 mg/kg/day for three days, 0.10 mg/kg/day for three days, 0.05 mg/kg/day for two days and 0.02 mg/kg/day for two days). The combined outcome of death or CLD at 28 days' PNA or at 36 weeks' PMA (13, 16) was significantly decreased by early corticosteroid treatment. There was no effect on mortality at 28 days' PNA, at 36 weeks' PMA, or at discharge (13, 16) . Corticosteroid treatment decreased CLD incidence at 28 days' PNA and at 36 weeks' PMA (8) (9) (10) (11) 13, 16) . On the basis of an analysis including data from the most recently published trials (19, 25) , 10 infants would need to be treated with corticosteroids to prevent one from developing CLD at 28 days' PNA or at 36 weeks' PMA.
Weaning from mechanical ventilation was more successful in infants treated with dexamethasone (13, 16) . The use of additional systemic dexamethasone by clinicians outside of the study protocols (open-label use) was decreased (13, 16) .
The incidences of hypertension (16) , hyperglycemia (13) , insulin therapy for hyperglycemia (16) , gastrointestinal bleeding (16) or perforation (13) , and hypertrophic obstructive cardiomyopathy (13) were increased by early corticosteroid treatment. The rates of pulmonary air leaks (13) and patent ductus arteriosus were decreased (13, 16) . There was no difference in the incidence of infection (13, 16) , necrotizing enterocolitis (NEC) (16) , intraventricular hemorrhage (13, 16) or severe retinopathy of prematurity (13, 16) . Weight gain was decreased during dexamethasone therapy (13, 16) . A borderline increased risk of periventricular leukomalacia (PVL) in the infants who received dexamethasone was noted in one (13) but not in the other recent systemic review (16) . In an update of the review by Shah and Ohlsson (16) , including the two recently published studies (n=1096) (19, 25) , the relative risk of PVL was 1.41 (95% CI 0.93 to 2.13). Long term outcomes are shown in Table 1 . 
Systemic moderately early postnatal corticosteroid therapy (seven to 14 days' PNA)
The most current reviews were published in 2001 (14, 16) . Infants in the studies included in the metaanalyses were preterm and dependent on mechanical ventilation with oxygen at enrollment (9) (10) (11) 14, 16) . All trials used dexamethasone. The drug was administered intravenously for two to 42 days, starting between seven and 14 days of age or given as a pulse dose for three days at 10-day intervals until the infant no longer required supplemental oxygen or ventilation, or had reached 36 weeks' PMA. The initial dosage was 0.5 mg/kg/day, which was maintained for the duration of the study period, decreased over seven to 42 days or followed by inhaled budesonide (9, 14, 16) . The combined outcome of death or CLD was decreased at 28 days' PNA and at 36 weeks' PMA (14,16). Mortality was not decreased in the treatment group at the time of discharge (14, 16) . In one review, mortality was not decreased at 28 days' PNA or 36 weeks' PMA (16) ; the other showed decreased mortality at 28 days' PNA (14) . The incidence of CLD at 28 days' PNA and 36 weeks' PMA (14,16) was decreased. The number of infants who needed to be treated with dexamethasone was seven and four to prevent CLD at 28 days' PNA and 36 weeks' PMA, respectively (16) . Infants were more likely to be extubated by seven and 28 days after initiation of treatment with dexamethasone (14, 16) . However, the duration of hospitalization or need for supplemental oxygen was not decreased (16) . The subsequent use of additional systemic steroids in the infants who had received dexamethasone during the study period was decreased (14, 16) .
The incidences of pneumothorax, severe retinopathy of prematurity, intraventricular hemorrhage and NEC were not increased (14, 16) . Infants in the dexamethasone group had an increased risk of developing hypertension (14, 16) . The two reviews differed in reporting statistically significant differences between treatment and control groups for hyperglycemia, gastrointestinal bleeding, hypertrophic obstructive cardiomyopathy and infection (14, 16) . Long term outcomes are shown in Table 2 .
Systemic delayed postnatal cortcosteroid therapy (older than three weeks of age)
There are two overlapping systematic reviews on systemic corticosteroid use started after three weeks of age (12, 15) . All infants enrolled in the primary studies were preterm and were dependent on oxygen or mechanical ventilation at approximately three weeks of age and older, with or without abnormalities of CLD evident on chest radiographs. Dexamethasone was administered intravenously or enterally at 0.5 to 1 mg/kg/day for a duration of three days to three weeks. The dosage was then tapered every three days in different ways; in some studies, the infants subsequently received hydrocortisone.
The combined outcome of death or CLD at 36 weeks' PMA was decreased by dexamethasone treatment. Dexamethasone did not affect survival at discharge or duration of hospitalization, but fewer infants were discharged home from the hospital on oxygen therapy. Extubation was facilitated by seven and 28 days after initiation of the treatment. Dexamethasone also improved respiratory compliance and decreased the need for oxygen supplementation, resulting in a borderline significant decrease in the incidence of CLD at 36 weeks' PMA. Late rescue treatment with dexamethasone was decreased in the treated infants. The risk of hypertension was increased by dexamethasone, but there was no difference in incidence of infection, NEC or gastrointestinal bleeding compared with controls. More infants in the dexamethasone group than in the control group experienced poor weight gain or even weight loss (12, 15) . Long term outcomes are shown in Table 3 . 
Inhaled steroids
Two systematic reviews (12, 26) address the effectiveness of inhaled corticosteroids to prevent CLD in ventilated infants with VLBW enrolled within two weeks after birth. No benefit of inhaled corticosteroids was shown, except the borderline significant decrease of subsequent administration of systemic dexamethasone. It is uncertain whether inhaled corticosteroids simply do not work for this condition or whether the type, dosage or delivery methods were inadequate. Other meta-analyses studied infants with VLBW enrolled after two weeks of age, with administration of inhaled corticosteroids for one to four weeks (12, 27) . Inhaled corticosteroids appeared to improve the extubation rate; however, there was heterogeneity among studies for this finding. No other differences were found, possibly because of lack of statistical power. Additional studies may help to determine whether inhaled corticosteroids decrease the need for systemic treatment or facilitate extubation.
Neurodevelopmental outcome
Two systematic reviews are available that focus on mortality and long term neurodevelopment of infants enrolled in randomized controlled trials of corticosteroids (11, 28) . In one review of five trials (31) (32) (33) (34) (35) (36) (37) , 475 (91%) of 522 survivors were followed. Mortality was not significantly different in the steroid and control groups (11) . Motor dysfunction was significantly greater with postnatal corticosteroid treatment, with an event rate difference of 11.9% favouring the controls (95% CI 4.6 to 19.2). The rate of survival free of motor dysfunction was lower in the postnatal corticosteroid-treated group (event rate difference of 7.8% favouring controls [95% CI 0.5 to 15.1]). Barrington (28) identified three additional trials (29, (38) (39) (40) that reported on long term outcome after postnatal exposure to corticosteroids. These eight studies represent 1052 infants; 292 of them died and 679 (89%) of the 760 survivors were followed for one year or longer. One important difficulty in evaluating long term effects of corticosteroids is that many control subjects were treated with open-label dexamethasone after the initial study period. Barrington (28) tried to take this into account by arbitrarily dividing the studies into two groups on the basis of whether they had less than 30% contamination (corticosteroids given to infants in the control group) (group 1), or more than 30% contamination or did not report on contamination (group 2). The outcomes evaluated were the incidences of cerebral palsy and neurodevelopmental impairment; the latter was defined as a developmental score more than two SD below the mean, or cerebral palsy or blindness.
The studies demonstrated a relative risk of neurodevelopmental impairment among surviving children exposed to corticosteroids of 1.34 (95% CI 1.09 to 1.64), compared with controls (28) . In the four studies with less than 30% contamination, the relative risk was 1.66 (95% CI 1.26 to 2.19) (28) . Including all studies, the relative risk of developing cerebral palsy in the surviving infants exposed to corticosteroids was 2.02 (95% CI 1.51 to 2.71) (28) . For infants from studies with less than 30% contamination, the relative risk of developing cerebral palsy among exposed infants was 2.89 (95% CI 1.96 to 4.27) (28). Thus, there appears to be a trend in the size of the apparent effect, which decreases as the degree of contamination increases (28) .
Three additional trials (19, 20, (41) (42) (43) (44) that reported long term outcomes after exposure to corticosteroids for the prevention or treatment of CLD were identified, increasing the sample size to a total of 870 children evaluated at one year of age or later (Tables 1-3 ). The identified trials are heterogeneous in the study populations, timing and dosage of postnatal corticosteroid treatment, crossover rates, event rates in the control groups, follow-up rates, time of assessment of neurodevelopment, and instruments used to assess neurodevelopment. Furthermore, not all are peerreviewed publications. Discrepancies between results reported in abstracts and full publications of the same randomized controlled trial are common (45) . Therefore, the data were not combined using meta-analytic techniques; instead, available details are presented in Tables 1 to 3 .
DISCUSSION
Systemic dexamethasone administration with the intent to prevent or treat CLD in the preterm infant does not affect mortality by the time of discharge or length of hospitalization. Early and moderately early systemic administration of dexamethasone decreases the incidence of CLD at 28 days' PNA and 36 weeks' PMA and allows for earlier extubation and fewer ventilator days. However, for these short term benefits, there are many short term adverse effects, including hyperglycemia often requiring insulin therapy, hypertension, gastrointestinal bleeding and intestinal perforation, hypertrophic obstructive cardiomyopathy, poor weight gain and poor growth of the head circumference, and a trend toward higher incidence of PVL.
The short term pulmonary benefits of systemic dexamethasone do not appear to confer long term benefits. Survival does not improve after dexamethasone administration. Furthermore, data indicating an increased incidence of neurodevelopmental delay and cerebral palsy raise serious concerns about adverse long term outcomes.
Dexamethasone is a potent anti-inflammatory corticosteroid. The pharmacological doses commonly used in trials and in practice are more than 10 to 15 times the estimated physiological secretion rate of cortisol in neonates. Furthermore, the limited pharmacokinetic data available in infants with extremely low birth weight indicate a prolonged half-life of dexamethasone compared with that in children and adults (46, 47) . High levels of dexamethasone may increase the rate of adverse effects. Possible alternatives to dexamethasone that may have fewer adverse effects include methylprednisolone, low hydrocortisone doses administered before chronic lung changes have developed or inhaled corticosteroids (48) . These interventions require further investigation. However, it is uncertain whether neurodevelopmental abnormalities are linked to the systemic use of corticosteroids in general or just to dexamethasone (28) .
The additional three trials noted in the tables (19, 20, (41) (42) (43) (44) increased the sample size by 191 children followed compared with the review by Barrington (28) , and by 395 compared with the review by Doyle and Davis (11) ; this increase in sample size would affect the results of these two previously published meta-analyses (11, 28) . The results of the three additional trials support the concept that corticosteroids should not be used routinely to prevent or treat infants at high risk of developing CLD or those with established CLD.
In view of the concerns regarding short and long term adverse effects, dexamethasone should not be routinely used to prevent or treat CLD. Enough uncertainty remains with regard to short and long term benefits and harms of corticosteroids to justify further well-designed and executed trials that would use a combination of survival and long term developmental impairments as the primary outcome.
SUMMARY
• Systemic administration of dexamethasone to preterm infants who are mechanically ventilated decreases the incidences of CLD and extubation failure but does not decrease overall mortality.
• Treatment of infants with VLBW with dexamethasone is associated with an increased risk of short and long term complications, including impaired growth and neurodevelopmental delay.
• No substantial short or long term benefits have been demonstrated from the use of inhaled corticosteroids in the prevention or treatment of CLD.
RECOMMENDATIONS
• On the basis of limited short term benefits, the absence of long term benefits, and the number of serious short and long term complications, the routine use of systemic dexamethasone for the prevention or treatment of CLD in infants with VLBW is not recommended.
• Postnatal use of systemic dexamethasone for the prevention or treatment of CLD should be limited to carefully designed randomized double-masked controlled trials. The primary outcome of these trials should be survival without long term developmental impairments, and the potential confounding factors of contamination and crossover should be avoided.
• Long term neurodevelopmental assessment of infants who are or have been subjects in trials of dexamethasone to prevent or treat CLD is strongly encouraged.
• Clinical trials investigating the use of alternative anti-inflammatory corticosteroids, systemic and inhaled, are required before further recommendations can be made.
• Outside the context of a randomized controlled trial, the use of corticosteroids should be limited to exceptional clinical circumstances (eg, an infant on maximal ventilatory and oxygen support). In those circumstances, parents should be fully informed about the known short and long terms risks and agree to treatment.
